NCT07075562Completed
TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
Effects of Transcatheter Hepatic Arterial Chemoembolization (TACE) and Bevacizumab Arterial Perfusion on Tumor Load and Angiogenesis in Patients With Hepatocellular Carcinoma Invading Portal Vein
Source: ClinicalTrials.gov · Last updated 20 Jul 2025
Brief summary (registry, in English)
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with hepatocellular carcinoma (HCC) invading the portal vein. The study aims to evaluate the effects on tumor load, angiogenesis, and survival outcomes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 180 (actual)
- First submitted
- 10 Jul 2025
- Start date
- 1 Jun 2021
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- The First Hospital of Hebei Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07075562
What you commit to
- Study type: Interventional
- Participants enrolled: 180
- From 1 Jun 2021 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior or planned liver transplantation.
Other illness
- History of other malignancies within the past five years.
- Severe comorbidities (e.g., decompensated cirrhosis, active bleeding, or cardiac disease).
- Known hypersensitivity to bevacizumab or other components of the treatment.
Other
- Pregnant or lactating women.
Who the study is looking for
- Aged between 18 and 70 years.
- Confirmed diagnosis of Hepatocellular Carcinoma (HCC) with radiological evidence of portal vein invasion.
- Preserved liver function (Child-Pugh class A or B).
- Absence of severe cardiac, renal, or other vital organ dysfunctions.
- Complete clinical and follow-up data available.
- Provided written informed consent.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.